• Temporal Transcriptomics Maps Host-Directed EBOV Therapy

  2026-09-09

  This preprint combines time-series transcriptomics, network biology, causal inference, and functional screening to identify host programs that Ebola virus exploits over distinct infection phases. The work prioritizes RELB, LDLR, and MYC as functional host factors and identifies Sorafenib and Thioguanine as candidate inhibitors of EBOV replication, while emphasizing that the findings require further validation because the study has not been peer reviewed.

• Magnetic Stimulation Targets GABAA ε in Schizophrenia

  2026-09-09

  This Molecular Psychiatry study identifies the GABAA receptor ε subunit, encoded by Gabre, in the left prelimbic cortex as a mechanistically actionable target for schizophrenia-like behaviors in mice. By combining selective magnetic stimulation with genetic knockdown and conditional knock-in models, the authors connect regional GABRE regulation with synaptic plasticity and behavioral rescue.

• tFUS, Nespas/miR-383-3p, and SHP2 in Stroke

  2026-09-08

  This study identifies a molecular explanation for the anti-inflammatory effects of low-intensity transcranial focused ultrasound after ischemic stroke. Its data connect tFUS with the Nespas/miR-383-3p/SHP2 pathway and reduced microglial NLRP3 inflammasome activation, providing a mechanistic framework for future stroke-neuroinflammation studies.

• RRP Restores Lipid Metabolism in Hepatic IRI

  2026-09-08

  The reference study shows that Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury by correcting hepatocyte cholesterol imbalance through an AMPK–mTOR-centered mechanism. Its main innovation is the connection of AMPK activation with reduced SCAP–SREBP2 cholesterol synthesis and enhanced LXRα-dependent cholesterol efflux, providing a mechanistic framework for lipid-focused liver injury research.

• Small Molecule Inhibitor for CK2/ERK8 Studies

  2026-09-07

  B7464 provides a practical kinase-perturbation tool for connecting CK2 and ERK8 signaling with phosphorylation, protein interactions, and condensate-related assays. This guide distinguishes evidence from workflow recommendations so researchers can test pathway effects without assuming that kinase inhibition directly reproduces the nucleocapsid-condensate disruption reported for GCG.

• Bazedoxifene and IL-6/GP130 Cancer Signaling

  2026-09-07

  This review presents Bazedoxifene, an established selective estrogen receptor modulator, as a potential inhibitor of IL-6/GP130 signaling and a candidate for oncology drug repurposing. Its synthesis of computational, mechanistic, and preclinical evidence supports further testing while emphasizing that target validation, exposure, and clinical efficacy remain unresolved.

• Praeruptorin A: A Translational Mechanism Map

  2026-09-05

  Praeruptorin A is an angular pyranocoumarin compound with reported activity across ferroptosis, inflammation, intestinal barrier injury, cardiomyopathy research, and hepatocellular carcinoma invasion. This thought-leadership perspective converts its multi-pathway profile into a practical framework for mechanism validation, model selection, and translational prioritization.

• p38α Dephosphorylation and Dual-Action Inhibitors

  2026-09-04

  The reference study shows that kinase inhibitors can do more than block p38α catalytic activity: by stabilizing a specific activation-loop conformation, selected compounds also accelerate WIP1-mediated dephosphorylation. Structural and biochemical evidence provides a framework for designing inhibitors that combine direct kinase blockade with phosphatase-facilitated pathway shutdown.

• GSK2606414 for PERK Inhibition Workflows

  2026-09-04

  Build cleaner ER stress experiments with GSK2606414, a potent and selective PERK inhibitor suited to pathway validation, translational disease models, and mechanism-focused assay design. This guide connects PERK signaling to Nrf2 readouts while emphasizing controls, timing, stock handling, and interpretation limits.

• Aprotinin (BPTI): Mechanism and Research Use

  2026-09-03

  Aprotinin, or bovine pancreatic trypsin inhibitor, is a reversible Kunitz-type serine protease inhibitor with research relevance to fibrinolysis, inflammation, and cardiovascular surgery blood management. Its assay-dependent potency, formulation limits, and historical clinical safety findings require context-specific experimental controls.

• AG-126 for ERK Signaling in Autism Models

  2026-09-03

  AG-126 (Tyrphostin AG-126) provides a practical ERK1/2 perturbation tool for connecting neuronal signaling measurements with neuroinflammation assays. This guide explains how to test ERK pathway involvement in Neuroligin 1 and D2-MSN models while separating evidence-backed applications from exploratory autism research.

• PGF2α/PTGFR and HIF-1α in Endometrial Breakdown

  2026-09-02

  A 2024 mouse menstrual-like model study identifies PGF2α signaling through PTGFR as a central regulator of endometrial breakdown and vascular permeability, with HIF-1α acting upstream at the Ptgfr promoter. The findings connect prostanoid signaling, angiogenic balance, and tissue shedding, while providing a receptor-focused framework for mechanistic follow-up studies.

• IPR-803 and uPAR–uPA Inhibition in Metastasis

  2026-09-02

  The reference study established IPR-803, identified as compound 4, as a directly binding small-molecule inhibitor of the uPAR–uPA protein–protein interaction and evaluated its biochemical, cellular, pharmacokinetic, and antimetastatic properties. Its combination of sub-micromolar receptor binding, inhibition of breast cancer cell invasion, measurable tumor exposure, and reduced lung metastasis provides a useful template for studying uPAR biology and developing protein–protein interaction inhibitors.

• Trametinib (GSK1120212) Workflow for MEK Research

  2026-09-01

  Build a reproducible Trametinib workflow that connects MEK-ERK target engagement with cell-cycle, apoptosis, and translational readouts. The guide also shows how the APEX2–TERT stem-cell findings can inform carefully bounded, exploratory oncology assays without implying a direct mechanism that has not been demonstrated.

• Vemurafenib (PLX4032) in Melanoma Research

  2026-09-01

  Vemurafenib (PLX4032) provides a practical BRAF V600E perturbation for measuring melanoma cell proliferation inhibition, pathway rebound, and resistance evolution. This workflow connects dose-response assays with multi-omics-informed experiments, including ARID1A-dependent resistance and melanoma xenograft tumor regression studies.

8050 records 1/537 page Next 12345 下5页 Last page